^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    busulfan

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    5d
    Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P=N/A, N=31, Recruiting, Peking University People's Hospital | Phase classification: P4 --> P=N/A
    Phase classification
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan
    7d
    Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer (clinicaltrials.gov)
    P2, N=30, Completed, City of Hope Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    Chr del(5q)
    |
    etoposide IV • busulfan
    8d
    Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (clinicaltrials.gov)
    P2, N=260, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • etoposide IV • sirolimus • melphalan • fludarabine IV • busulfan
    9d
    Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial. (PubMed, Nat Med)
    Twenty-four newly diagnosed patients with GBM and unmethylated MGMT promoter were treated across eight cohorts following surgical resection and radiotherapy, testing Temferon doses ranging from 0.5 × 106 to 4.0 × 106 CD34+ cells kg-1 and different conditioning regimens (BCNU or busulfan, with or without thiotepa). Temferon is a safe and tolerable immunotherapeutic strategy in patients with newly diagnosed GBM. ClinicalTrials.gov: NCT03866109 .
    P1 data • Journal • First-in-human
    |
    CD34 (CD34 molecule)
    |
    thiotepa • busulfan • Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
    14d
    Squamous Cell Carcinoma of the Skin in a Teenager with Fanconi Anemia: A Challenging Treatment. (PubMed, Int J Mol Sci)
    Conditioning therapy included busulfan, thymoglobulin, and fludarabine, while graft-versus-host disease (GvHD) prophylaxis was administered with rituximab, methotrexate, and cyclosporine A. Nevertheless, he developed chronic cutaneous GVHD, which was treated for four years with ruxolitinib and tacrolimus, achieving only partial control...Surgery, radiation therapy, and immunotherapy with pembrolizumab led only to an initial partial response. This first pediatric case of immunotherapy for SCC in FA highlights the challenges of treating this rare patient group. Nevertheless, combining radiation therapy with immunotherapy may represent a possible option for disease control.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FANCA (FA Complementation Group A)
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Jakafi (ruxolitinib) • methotrexate • fludarabine IV • busulfan
    20d
    Precision Dosing of Busulfan in Children Undergoing haematopoietic stem-cell transplantation (HSCT)- A randomised controlled study to investigate the impact and feasibility of implementing pharmacogenomics into the busulfan dosing method for children undergoing haematopoietic stem-cell transplantation on target exposure attainment following dose 1. (ACTRN12626000610336)
    P=N/A, N=25, Not yet recruiting, Prof. Marc Ansari, Geneva University Hospitals
    New trial
    |
    fludarabine IV • busulfan
    21d
    Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN (clinicaltrials.gov)
    P1, N=102, Active, not recruiting, Jacqueline Garcia, MD | Trial completion date: Mar 2027 --> Mar 2030
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • NPM1 (Nucleophosmin 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • GATA2 (GATA Binding Protein 2) • DEK (DEK Proto-Oncogene) • RIT1 (Ras Like Without CAAX 1) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • Chr del(5q)
    |
    Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan
    26d
    Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P4, N=31, Recruiting, Sun Yuqian
    New P4 trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    fludarabine IV • thiotepa • busulfan
    26d
    NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan
    26d
    Haplo-Cord HSCT for AML/MDS (clinicaltrials.gov)
    P=N/A, N=180, Recruiting, Fujian Medical University Union Hospital
    New trial
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • KIT mutation
    |
    cytarabine • cyclophosphamide • melphalan • fludarabine IV • busulfan
    28d
    IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=30, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase classification: P2a --> P2
    Phase classification
    |
    CD34 (CD34 molecule)
    |
    bortezomib • busulfan
    30d
    Simple Interventions Can Improve Access to Autologous Stem Cell Transplant in Low- and Lower-Middle-Income Countries by Reducing Complexity, Lowering Costs, and Minimizing Infectious Risks. (PubMed, Pediatr Blood Cancer)
    In our cohort, the incorporation of ASCT into multimodality therapy was feasible with resource-adapted strategies; however, this did not translate into a meaningful improvement in survival outcomes when compared with our historical non-transplant cohort.
    Journal
    |
    CD34 (CD34 molecule)
    |
    melphalan • busulfan • plerixafor